tadalafil has been researched along with warfarin in 3 studies
Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (warfarin) | Trials (warfarin) | Recent Studies (post-2010) (warfarin) |
---|---|---|---|---|---|
1,742 | 392 | 1,089 | 36,573 | 2,143 | 14,728 |
Protein | Taxonomy | tadalafil (IC50) | warfarin (IC50) |
---|---|---|---|
Vitamin K epoxide reductase complex subunit 1 | Homo sapiens (human) | 0.0088 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Abadi, AH; Abdel-Halim, M; Engel, M; Fathalla, RK; Hammam, MA; Hartmann, RW; Hefnawy, A; Keeton, AB; Maher, A; Maxuitenko, Y; Piazza, GA; Racheed, NAS; Sigler, S | 1 |
Izzo, A; Khatwa, U; Kothare, SV; Kulik, T; McSweeney, J | 1 |
2 review(s) available for tadalafil and warfarin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
"Nocturnal seizures" in idiopathic pulmonary arterial hypertension.
Topics: Carbolines; Cardiac Output, Low; Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Oxygen Inhalation Therapy; Parasomnias; Seizures; Severity of Illness Index; Sleep Apnea Syndromes; Tadalafil; Treatment Outcome; Warfarin | 2013 |
1 other study(ies) available for tadalafil and warfarin
Article | Year |
---|---|
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Topics: Animals; Blood Proteins; Celecoxib; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Half-Life; Humans; Isoenzymes; Mice; Mice, Inbred C57BL; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2021 |